Four to Eight Years for Selling Unapproved Injectables and Devices: What the Scalpa Plea Means for Med Spa Owners

An Arizona skincare company spent about three years selling handheld devices, dermal filler, and an injectable botulinum toxin product to aesthetic practitioners. Its chief executive has now pleaded guilty in federal court in the Western District of Virginia and agreed to a prison term of four to eight years, $800,000 in forfeiture, and restitution. He was taken into custody in Colombia by the United States Marshals Service on a warrant that had been outstanding since 2024.

No patient injury was required. No Medicare billing. No kickback. The government proved that products moved in interstate commerce without FDA authorization, and that the company told buyers those products were outside FDA's reach. That combination produced the mail fraud counts, and the mail fraud counts produced the years.

If you own a med spa, run an MSO, distribute aesthetic devices, or sell injectables into that market, this is the enforcement model to read closely.

No patient injury. No Medicare billing. No kickback. Products moved in interstate commerce without FDA authorization, and the company told buyers those products were outside FDA's reach.

Key Takeaways

• Selling a Class III device without premarket approval or 510(k) clearance is a prohibited act under 21 U.S.C. § 331, with felony penalties under § 333.
• An injectable botulinum toxin product with no approved application is an unapproved new drug under 21 U.S.C. § 355, charged here as a standalone count.
• Telling buyers a regulated device is not subject to FDA regulation is what turned a regulatory case into mail fraud under 18 U.S.C. § 1341.
• The agreed disposition was four to eight years in prison, $800,000 in forfeiture, and restitution, with no allegation that a patient was harmed.
• Florida makes receiving prescription drugs from an unauthorized distributor a felony under Fla. Stat. § 499.0051, and South Florida remains an active federal district for aesthetic-product cases.

What Actually Happened

A federal grand jury in the Western District of Virginia returned a 34-count indictment in July 2024 against the president and chief executive of Scalpa, Inc., an Arizona corporation that marketed aesthetic devices and injectable products. The indictment charged 12 counts of mail fraud, 9 counts of wire fraud, 12 counts of introducing adulterated devices into interstate commerce, and 1 count of introducing an unapproved new drug into interstate commerce. The conduct period ran from roughly March 2018 through December 2020.

Four products carried the case. A fibroblast pen that discharged high-frequency electric current into the skin. A needle-free hyaluron pen. A branded hyaluronic acid dermal filler. And an injectable containing Clostridium botulinum type A neurotoxin complex sold under the company's own brand name.

Three of the four products were Class III devices, the highest risk classification FDA assigns. The fourth was an injectable toxin with no approved application. Every one of them was sold into working aesthetic practices.

Three of those are Class III devices, the highest risk classification FDA assigns, requiring either premarket approval or 510(k) clearance. The indictment alleged none had either. The toxin product had no approved New Drug Application and no approved Abbreviated New Drug Application, making it an unapproved new drug under 21 U.S.C. § 355.

He was arrested abroad in late 2025 and returned to face the indictment. According to the July 31, 2026 announcement from the U.S. Attorney's Office for the Western District of Virginia, he pleaded guilty to three counts, one mail fraud, one adulterated device, and the unapproved new drug count, and agreed that he committed all 34 crimes charged. The plea fixed the sentence at four to eight years, plus $800,000 in forfeiture and restitution.

The warrant had been outstanding since 2024. He was taken into custody in Colombia by the United States Marshals Service and returned to the Western District of Virginia to face the indictment.

The Theory of the Case, and Why It Should Worry Operators

Read the charging structure again. The FDCA counts are the smaller half of this case. The bulk of the indictment was mail and wire fraud, and the fraud theory was not that the products did not work. It was that the company represented to purchasers that the devices were not subject to FDA regulation.

That is the move to understand. A pure 21 U.S.C. § 331 violation is a misdemeanor on a first offense under § 333(a)(1), with no proof of knowledge required, and a three-year felony under § 333(a)(2) when committed with intent to defraud or mislead. Standing alone, that is not a case that produces eight years. Layer 18 U.S.C. § 1341 and § 1343 on top of it, each carrying twenty years, and the arithmetic changes completely.

What supplies the fraud element is the regulatory-status representation. Every line of marketing copy claiming a product falls outside FDA's authority, every training deck calling a pen a cosmetic tool rather than a device, becomes an affirmative misrepresentation the moment the government concludes the product was regulated. Those statements live in email, course materials, and shipped brochures. That is why the mail counts existed at all.

FDA has warned publicly for years about unapproved and counterfeit botulinum toxin products and the botulism-type adverse events tied to them. An operator injecting an unapproved toxin is not sitting in a gray area the agency has ignored.

Exposure and Charges

The statutes in this space stack predictably.

• Prohibited acts under 21 U.S.C. § 331, including introduction of an adulterated device, a misbranded product, or an unapproved new drug into interstate commerce, penalized under § 333.
• Device authorization failures under 21 U.S.C. § 360 and § 360e, which is where the Class III premarket question lives.
• Mail fraud, 18 U.S.C. § 1341, and wire fraud, 18 U.S.C. § 1343, each twenty years per count, driven by representations about regulatory status, sourcing, or product identity.
• Conspiracy under 18 U.S.C. § 1349, which reaches nearly every multi-party sourcing, training, and distribution arrangement in this industry.
• Health care fraud under 18 U.S.C. § 1347 wherever a federal payor touchpoint exists, which is more often than clinic owners assume once a procedure gets coded as medically necessary.
• Criminal forfeiture under 18 U.S.C. § 981 and restitution, which in this case totaled $800,000 in forfeiture on top of the prison term.

How the Guidelines Turn Revenue Into Years

Sentencing in the fraud-driven version of these cases runs through U.S.S.G. § 2B1.1. Loss is generally calculated on gross receipts from the product line, not profit. A supply business that moved product for three years does not get to argue margins at sentencing. It argues about a revenue figure, and the guideline table is unforgiving above a few hundred thousand dollars.

That is the number that decides the case. Everything a defense lawyer does in the pre-indictment window, from product classification analysis to sourcing documentation, is ultimately aimed at the loss figure and at whether the conduct gets charged as fraud at all.

The Florida Piece

Florida sits on the receiving end of this supply chain, and that end carries its own criminal exposure. Under Fla. Stat. § 499.0051, knowingly purchasing or receiving a prescription drug from an unauthorized distributor is a felony. A Boca Raton or Fort Lauderdale med spa that bought an injectable from a training company, a conference vendor, or an unverified overseas supplier is exposed under state law independent of anything federal. The state file frequently becomes the roadmap for the federal one, because inspection records and purchase histories are the first thing an FDA Office of Criminal Investigations agent asks for.

The second Florida issue is who directed the injection. Where the ordering practitioner never performed a good faith examination, or where an unlicensed owner or technician drove the treatment decision, unlicensed practice of medicine under Fla. Stat. § 458.327 is a third-degree felony, and Florida prosecutors charge it against aesthetic providers rather than leaving it to a licensing board.

The Southern and Middle Districts of Florida, with FDA Office of Criminal Investigations, maintain a heavy footprint in aesthetic and weight-loss enforcement. A South Florida practice relying on a national vendor's compliance assurances is relying on a document that has never been tested in the district where it will be tested.

The Mistakes That Turn a Compliance Problem Into an Indictment

Trusting the vendor's regulatory representation. The seller told buyers the devices were not subject to FDA regulation. Those buyers still possessed and used unapproved Class III devices. A supplier's assurance is not a defense and it is not diligence. It is a document the government uses to show the clinic knew the question existed and stopped asking.

"A supplier's assurance is not a defense and it is not diligence. It is a document the government uses to show the clinic knew the question existed and stopped asking."— Aaron M. Cohen, AMC Defense Law

Cleaning up after contact. Pulling service pages, revising treatment menus, or editing supplier records after FDA or a U.S. Attorney's Office makes contact is obstruction under 18 U.S.C. § 1519, a twenty-year felony that has destroyed otherwise defensible matters.

Treating an FDA visit as administrative. FDA Office of Criminal Investigations agents conduct criminal investigations. A false or incomplete statement to a federal agent is a standalone five-year felony under 18 U.S.C. § 1001. Declining to answer until counsel arrives is not obstruction and it is not an admission.

Producing everything in response to a grand jury subpoena. A subpoena opens a negotiation about scope. It is not an instruction to hand over the practice management system and three years of vendor email.

Assuming the injector carries the risk alone. The government builds these cases at the ownership, marketing, and supply layer, because that is where intent gets written down.

Where the Defense Work Actually Happens

Before charges. The investigation that produced 34 counts ran for years before the grand jury saw it, and the record that convicted him, marketing copy, shipping records, training materials, was created by the company long before anyone thought a prosecutor would read it. A federal investigation defense lawyer engaged at the warning letter, civil investigative demand, or subpoena stage can establish whether the client is a witness, a subject, or a target, and can put sourcing documentation, product classification analysis, and the regulatory history in front of the government before agents finish a timeline without it. Employees contacted by agents need independent counsel rather than company counsel, and that separation has to happen early to mean anything.

Once a target letter arrives, the theory is fixed and the conversation moves from whether to how much. Pre-indictment is where charging decisions are still fluid, where product classification arguments still have somewhere to go, and where a white collar defense attorney can affect whether a matter resolves as a regulatory case or gets charged as fraud. That distinction here was the difference between a misdemeanor and eight years.

Common Questions

Contacted by FDA, Served With a Grand Jury Subpoena, or Received a Target Letter?

AMC Defense Law represents med spa and aesthetic clinic owners, MSO operators, device and injectable distributors, training companies, physicians, nurse practitioners, and physician assistants in federal investigations and prosecutions involving unapproved drugs and devices, misbranding, health care fraud, and related conduct. The firm's South Florida federal criminal defense practice is based in Boca Raton and handles matters throughout Florida and nationwide.

If FDA Office of Criminal Investigations, a state board, or a U.S. Attorney's Office has contacted you or your business, speak with a federal criminal defense attorney before you respond or produce anything. Contact the firm for a confidential consultation.

If you or your loved ones have been arrested or are under federal investigation, call Aaron M. Cohen, 24 hours a day to get help.